PL363175A1 - Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use - Google Patents

Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Info

Publication number
PL363175A1
PL363175A1 PL02363175A PL36317502A PL363175A1 PL 363175 A1 PL363175 A1 PL 363175A1 PL 02363175 A PL02363175 A PL 02363175A PL 36317502 A PL36317502 A PL 36317502A PL 363175 A1 PL363175 A1 PL 363175A1
Authority
PL
Poland
Prior art keywords
diagnostic
therapeutic use
envelope proteins
virus envelope
purified hepatitis
Prior art date
Application number
PL02363175A
Other languages
English (en)
Polish (pl)
Inventor
Geert Maertens
Fons Bosman
Erik Depla
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of PL363175A1 publication Critical patent/PL363175A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02363175A 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use PL363175A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26066901P 2001-01-11 2001-01-11
US31576801P 2001-08-30 2001-08-30
PCT/EP2002/000219 WO2002055548A2 (en) 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Publications (1)

Publication Number Publication Date
PL363175A1 true PL363175A1 (en) 2004-11-15

Family

ID=26948130

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02363175A PL363175A1 (en) 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Country Status (16)

Country Link
EP (1) EP1463753A2 (de)
KR (1) KR20020089371A (de)
CN (1) CN1547588A (de)
AR (1) AR032240A1 (de)
AU (1) AU2002238502B2 (de)
BR (1) BR0203518A (de)
CA (1) CA2400643A1 (de)
CZ (1) CZ20032164A3 (de)
HU (1) HUP0302416A2 (de)
IL (1) IL151033A0 (de)
MX (1) MXPA02008886A (de)
NO (1) NO20024325L (de)
PL (1) PL363175A1 (de)
RU (1) RU2313363C2 (de)
TR (1) TR200202169T1 (de)
WO (1) WO2002055548A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002252856A1 (en) 2001-04-24 2002-11-05 Innogenetics N.V. Expression of core-glycosylated hcv envelope proteins in yeast
EP1558283A2 (de) * 2002-11-08 2005-08-03 Innogenetics N.V. E1 und ns3 peptide enthaltende hcv impfstoffzusammensetzungen
EP1561470A1 (de) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV Vakzine beinhaltend das Hüllprotein E1 oder die korrespondierende DNA und mindestens ein antivirales Medikament
CN102659922B (zh) * 2003-09-22 2013-11-06 株式会社绿多肽 来源于c型肝炎病毒的肽
CN100365124C (zh) * 2005-10-27 2008-01-30 云南大学 一段丙型肝炎病毒特异性cDNA序列的应用
CN115980352A (zh) * 2022-12-30 2023-04-18 宁波博肽生物技术有限公司 一种hcv抗原包被预处理剂、抗原包被方法及检测试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69526636D1 (de) * 1994-07-29 2002-06-13 Innogenetics Nv Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung

Also Published As

Publication number Publication date
CZ20032164A3 (cs) 2003-10-15
IL151033A0 (en) 2003-04-10
WO2002055548A3 (en) 2004-08-05
AU2002238502B9 (en) 2002-07-24
NO20024325D0 (no) 2002-09-10
EP1463753A2 (de) 2004-10-06
NO20024325L (no) 2002-11-11
MXPA02008886A (es) 2003-04-25
RU2313363C2 (ru) 2007-12-27
TR200202169T1 (tr) 2004-06-21
RU2002121632A (ru) 2004-03-20
WO2002055548A8 (en) 2002-10-31
AU2002238502B2 (en) 2007-09-06
BR0203518A (pt) 2002-12-17
HUP0302416A2 (hu) 2003-10-28
WO2002055548A2 (en) 2002-07-18
CA2400643A1 (en) 2002-07-18
CN1547588A (zh) 2004-11-17
KR20020089371A (ko) 2002-11-29
AR032240A1 (es) 2003-10-29
AU2002238502A1 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
LU91328I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)
EP1391212A4 (de) Orale darreichungsformen und träger für orale darreichungsformen
HUP0102478A3 (en) Particles of hcv envelope proteins: use for vaccination
SI1404347T1 (sl) 4'-substituirani nukleozidi za zdravljenje bolezni posredovanih z virusom hepatitisa c
AP2001002301A0 (en) Inhibition of viral infection using monovalentantigen-binding proteins
PL366621A1 (en) Core-glycosylated hcv envelope proteins
IL147969A0 (en) Peptides that block viral infectivity and methods of use thereof
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
AU2158000A (en) Treatment of hepatitis c virus infections with interleukin-10
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
EP1401857A4 (de) Aufreinigung von humanem serumalbumin
PL373675A1 (en) Hepatitis b virus treatment
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
EP1141255A4 (de) Veränderte formen der hepatitis c virus ns3 protease
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
PL356640A1 (en) Treatment of viral infections using levovirintm
AU2002233424A1 (en) Peptides having affinity for the GP120 viral protein and use thereof
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
IL161138A0 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
EP1113777A4 (de) Neues hepatitis c viruspeptid und seine verwendung
IL145440A0 (en) Synthetic hcv envelope proteins and their use for vaccination
HK1067371A (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
HK1067035A (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AU2002332613A1 (en) Compositions and therapeutic methods for viral infection
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)